More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
This article was originally published in Pharmaceutical Approvals Monthly
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator
You may also be interested in...
Foundation says drug is exception to rule, and fronts more funding.
Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.
10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.